The Danish drugmaker Novo Nordisk argues that semaglutide, the active ingredient in Ozempic and Wegovy, are too complex for those manufacturers to make safely.
Related Posts
The Fed could find itself in a policy Catch-22 if tariffs spike inflation and slow growth
Many economists expect the tariffs both to raise prices and shave the pace of gross domestic product.
Amazon to halt some of its DEI programs: Internal memo
The company is in the process of “winding down outdated programs and materials” as part of a broader review of hundreds of initiatives.
New York Gov. Hochul will not remove Mayor Eric Adams ‘right now’
The DOJ is seeking to dismiss its criminal case against Adams, citing the need for his cooperation on Trump immigration enforcement policies.